Maze Therapeutics (MAZE) EPS (Weighted Average and Diluted) (2024 - 2026)
Maze Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.45 in Q1 2026, up 25.0% quarter-over-quarter from -$0.6 in Q4 2025, and up 60.87% year-over-year from -$0.28 in Q1 2025.
Maze Therapeutics' EPS (Weighted Average and Diluted) history runs 3 years deep, the most recent figure standing at -$0.45 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 60.87% year-over-year to -$0.45; the TTM figure through Mar 2026 stood at -$2.48 (up 74.17% YoY), while the FY2025 annual figure was -$3.05, down 344.0% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.45 for Q1 2026 at Maze Therapeutics, up from -$0.6 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.22 in Q2 2024 to a low of -$13.91 in Q1 2024.
- A 3-year average of -$2.89 and a median of -$0.77 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 93.56% in 2025 and fell as far as 123.91% in 2025.
- Maze Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.42 in 2024, then soared by 57.75% to -$0.6 in 2025, then grew by 25.0% to -$0.45 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.45, -$0.6, and -$0.66 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | -0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -0.60 |
| Sep 30, 2025 | -0.66 |
| Jun 30, 2025 | -0.77 |
| Mar 31, 2025 | -1.15 |
| Dec 31, 2024 | -1.42 |
| Sep 30, 2024 | -10.25 |
| Jun 30, 2024 | 3.22 |
| Mar 31, 2024 | -13.91 |